Overview

Phase I Study of GSK233705 in Healthy Japanese Male Subjects

Status:
Completed
Trial end date:
2008-12-20
Target enrollment:
Participant gender:
Summary
This is a randomised, double blind, placebo-controlled, 2-parts study to investigate the safety, tolerability, and pharmacokinetics of single and repeat inhaled doses of GSK233705 from a novel dry powder device in healthy Japanese male subjects.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline